Prostate Cancer
Advertisement
A recent study assessed pathologic and short-term oncological and survival outcomes of prostate cancer surgical approaches.
The phase II UpFrontPSMA study evaluated the use of [177Lu]Lu-PSMA-617 administered before docetaxel.
Clarity's head-to-head trial evaluates diagnostic performance of 64Cu-SAR-bisPSMA vs 68Ga-PSMA-11.
In part six of this roundtable series, the panelists finish their discussion by reviewing immunotherapy in prostate cancer.
In part five of this roundtable series, the panelists discuss radiopharmaceuticals in the overall landscape of mCRPC.
In part four of this roundtable series, the panelists discuss CRPC and the typical patterns of presentation.
Part three of this roundtable delves into genomic biomarkers and the use of doublet and triplet therapies for mHSPC.
Part two of the roundtable series explores ADT and novel hormonal therapies for patients with prostate cancer.
Part one of a roundtable series on prostate cancer, focusing on defining mHSPC and mCRPC.
GETUG 14 recruited patients with both intermediate- and high-risk PCa, randomizing them to receive RT or stADT plus RT.
Dr. Greenstein shares insights on the overall survival benefit of apalutamide over enzalutamide in a recent real-world study.
The panelists examine the existing data for T cell engagers in CRPC and how the data might affect clinical practice.
The panelists discuss T cell engagers, including an introduction and discussion of cytokine release syndrome.
The panel discusses the emerging field of PSMA-targeted alpha radioligand therapy, with a focus on HK2.
The panel discusses the results of PEACE-3, which evaluated enzalutamide with or without radium-223 for MCRPC.
The panel discusses two significant trials in metastatic hormone-sensitive prostate cancer.
The final segment of this roundtable series discusses radiopharmaceuticals and PARP inhibitors.
Part five of this roundtable series covers data and insights from the ARANOTE and PEACE 3 trials.
Part four of a PCa roundtable series focuses on the effectiveness of ADT with triplet therapy.
Part 2 of the Radioligands session from Uromigos Live 2024 features a discussion on the SPLASH results from ESMO 2024.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.